Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
ALK
FISH
NGS
NSCLC
NTRK
RET
ROS1
fusion
lung cancer
molecular testing
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
11 04 2023
11 04 2023
Historique:
received:
09
02
2023
revised:
05
04
2023
accepted:
10
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
The ability to identify the broadest range of targetable gene fusions is crucial to facilitate personalized therapy selection for advanced lung adenocarcinoma (LuADs) patients harboring targetable receptor tyrosine kinase (RTK) genomic alterations. In order to evaluate the most effective testing approach for LuAD targetable gene fusion detection, we analyzed 210 NSCLC selected clinical samples, comparing in situ (Fluorescence In Situ Hybridization, FISH, and ImmunoHistoChemistry, IHC) and molecular (targeted RNA Next-Generation Sequencing, NGS, and RealTime-PCR, RT-PCR) approaches. The overall concordance among these methods was high (>90%), and targeted RNA NGS was confirmed to be the most efficient technique for gene fusion identification in clinical practice, allowing the simultaneous analysis of a large set of genomic rearrangements at the RNA level. However, we observed that FISH was useful to detect targetable fusions in those samples with inadequate tissue material for molecular testing as well as in those few cases whose fusions were not identified by the RNA NGS panel. We conclude that the targeted RNA NGS analysis of LuADs allows accurate RTK fusion detection; nevertheless, standard methods such as FISH should not be dismissed, as they can crucially contribute to the completion of the molecular characterization of LuADs and, most importantly, the identification of patients as candidates for targeted therapies.
Identifiants
pubmed: 37190044
pii: cells12081135
doi: 10.3390/cells12081135
pmc: PMC10137127
pii:
doi:
Substances chimiques
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Cell Dev Biol. 2016 Sep 05;4:89
pubmed: 27656642
Front Oncol. 2022 Nov 07;12:1038774
pubmed: 36419889
J Mol Diagn. 2013 Jul;15(4):415-53
pubmed: 23562183
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Per Med. 2022 Sep;19(5):395-401
pubmed: 35801400
Oncotarget. 2015 Oct 13;6(31):30592-603
pubmed: 26435479
Front Oncol. 2020 Apr 15;10:489
pubmed: 32351889
Clin Lung Cancer. 2021 Jul;22(4):e637-e641
pubmed: 33642178
Cancer Treat Rev. 2022 Sep;109:102430
pubmed: 35777135
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Ann Oncol. 2021 Mar;32(3):337-350
pubmed: 33455880
Genes Chromosomes Cancer. 2022 May;61(5):244-260
pubmed: 34997651
Nat Med. 2014 Dec;20(12):1479-84
pubmed: 25384085
NPJ Precis Oncol. 2021 Jul 20;5(1):69
pubmed: 34285332
Clin Gastroenterol Hepatol. 2022 Oct 22;:
pubmed: 36280101
Eur J Cancer. 2022 Oct;174:200-211
pubmed: 36044814
Genes Chromosomes Cancer. 2020 Mar;59(3):178-188
pubmed: 31652375
J Mol Diagn. 2021 Dec;23(12):1749-1760
pubmed: 34562614
Biomed Res Int. 2013;2013:757490
pubmed: 23484153
Lung Cancer. 2019 Aug;134:225-232
pubmed: 31319985
Diagnostics (Basel). 2020 Dec 15;10(12):
pubmed: 33333743
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Cancers (Basel). 2019 Sep 05;11(9):
pubmed: 31491926